{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:16:51Z","timestamp":1776302211044,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bone.2020.115502","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T02:13:49Z","timestamp":1593051229000},"page":"115502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study"],"prefix":"10.1016","volume":"139","author":[{"given":"Jie","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2020.115502_bb0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.bone.2020.115502_bb0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","article-title":"Proton-pump inhibitors: understanding the complications and risks","volume":"14","author":"Malfertheiner","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.bone.2020.115502_bb0015","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1572-0241.2007.01106.x","article-title":"The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use","volume":"102","author":"Targownik","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0025","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bone.2020.115502_bb0030","author":"FDA Drug Safety Communication"},{"issue":"3","key":"10.1016\/j.bone.2020.115502_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1370\/afm.1243","article-title":"Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies","volume":"9","author":"Eom","year":"2011","journal-title":"Ann. Fam. Med."},{"issue":"12","key":"10.1016\/j.bone.2020.115502_bb0040","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/MEG.0000000000001198","article-title":"Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis","volume":"30","author":"Islam","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0045","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.bone.2010.12.015","article-title":"Meta-analysis: risk of fractures with acid-suppressing medication","volume":"48","author":"Kwok","year":"2011","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2020.115502_bb0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","article-title":"Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.bone.2020.115502_bb0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/MEG.0b013e328348a56a","article-title":"Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis","volume":"23","author":"Ye","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bone.2020.115502_bb0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","article-title":"Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies","volume":"124","author":"Yu","year":"2011","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S8756-3282(99)00097-6","article-title":"Fracture risk after surgery for peptic ulcer disease: a population-based cohort study","volume":"25","author":"Melton","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115502_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e372","article-title":"Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study","volume":"344","author":"Khalili","year":"2012","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.bone.2020.115502_bb0080","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0090","first-page":"318","article-title":"Which deprivation? A comparison of selected deprivation indexes","volume":"13","author":"Morris","year":"1991","journal-title":"J. Public Health Med."},{"issue":"7","key":"10.1016\/j.bone.2020.115502_bb0095","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/pds.1062","article-title":"An application of propensity score matching using claims data","volume":"14","author":"Seeger","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2020.115502_bb0100","doi-asserted-by":"crossref","first-page":"d3651","DOI":"10.1136\/bmj.d3651","article-title":"Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores","volume":"342","author":"Collins","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.bone.2020.115502_bb0105","doi-asserted-by":"crossref","first-page":"229 e15","DOI":"10.1016\/j.amjmed.2016.09.006","article-title":"Intermittent nitrate use and risk of hip fracture","volume":"130","author":"Misra","year":"2017","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115502_bb0110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00198-012-2053-3","article-title":"Diuretic initiation and the acute risk of hip fracture","volume":"24","author":"Berry","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2020.115502_bb0115","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-014-2662-0","article-title":"Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation","volume":"25","author":"Misra","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2020.115502_bb0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/EDE.0b013e31825fa218","article-title":"Additive interaction in survival analysis: use of the additive hazards model","volume":"23","author":"Rod","year":"2012","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.bone.2020.115502_bb0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bone.2020.115502_bb0130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study","volume":"172","author":"Sturmer","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bone.2020.115502_bb0135","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.bone.2020.115502_bb0140","first-page":"178","article-title":"Statistical methods in cancer research. Volume II\u2013the design and analysis of cohort studies","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci. Publ."},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00001648-199507000-00005","article-title":"Dose-response and trend analysis in epidemiology: alternatives to categorical analysis","volume":"6","author":"Greenland","year":"1995","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12913-018-3358-5","article-title":"Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists\u2019 effect on prescribing practice at a tertiary hospital","volume":"18","author":"Luo","year":"2018","journal-title":"BMC Health Serv. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0155","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.annepidem.2014.01.004","article-title":"Proton-pump inhibitor use and hip fractures in men: a population-based case-control study","volume":"24","author":"Adams","year":"2014","journal-title":"Ann. Epidemiol."},{"issue":"6","key":"10.1016\/j.bone.2020.115502_bb0160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/phar.1410","article-title":"Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting","volume":"34","author":"Cea Soriano","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.bone.2020.115502_bb0165","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.2026","article-title":"Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study","volume":"19","author":"Chiu","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients","volume":"139","author":"Corley","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bone.2020.115502_bb0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00223-014-9855-6","article-title":"The relationship between proton pump inhibitor adherence and fracture risk in the elderly","volume":"94","author":"Ding","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0180","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: report from the Canadian multicenter osteoporosis study","volume":"24","author":"Fraser","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2020.115502_bb0185","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2016.09.019","article-title":"Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients","volume":"69","author":"Lenihan","year":"2017","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00198-017-4262-2","article-title":"Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study","volume":"29","author":"Lin","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115502_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00198-018-4788-y","article-title":"Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies","volume":"30","author":"Poly","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2020.115502_bb0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00198-010-1337-8","article-title":"Use of proton pump inhibitors and risk of hip\/femur fracture: a population-based case-control study","volume":"22","author":"Pouwels","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2020.115502_bb0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.bone.2020.115502_bb0210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative","volume":"170","author":"Gray","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115502_bb0215","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bone.2012.09.028","article-title":"Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region","volume":"52","author":"Reyes","year":"2013","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2020.115502_bb0220","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/oxfordjournals.aje.a008895","article-title":"Confounding by indication and channeling over time: the risks of beta 2-agonists","volume":"144","author":"Blais","year":"1996","journal-title":"Am. J. Epidemiol."},{"issue":"9026","key":"10.1016\/j.bone.2020.115502_bb0225","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(05)64664-8","article-title":"Observational studies of drug safety","volume":"348","author":"Walker","year":"1996","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bone.2020.115502_bb0230","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"7634","key":"10.1016\/j.bone.2020.115502_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.39416.559942.BE","article-title":"Non-drug industry funded research","volume":"336","author":"Bruzzi","year":"2008","journal-title":"BMJ"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:47:31Z","timestamp":1757612851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220302829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":47,"alternative-id":["S8756328220302829"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115502","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115502"}}